Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Adam, aggressive, aim, allogeneic, annum, appeal, axicabtagene, billion, biosimilar, Blueprint, borrowing, BPCIA, ceiling, ciloleucel, CMS, Coast, Congressional, coupled, CRS, curative, cytokine, delisted, deregulation, diagnosed, die, differentiated, diffuse, disabled, District, domestic, easier, Eighty, encourage, entertain, entirety, EU, fall, fatal, feedback, follicular, forefront, formulary, FSS, fueled, furniture, genetically, Gilead, graft, Guard, guideline, GvHD, hindsight, hospital, HSCT, identification, implicit, incentivize, increasingly, inflation, inflationary, inherited, injectable, inNote, Inspector, Kymriah, laid, lived, Logal, lymphocytic, lymphoplasmacytic, mantle, military, modality, mortality, nearest, needy, neurologic, NHL, notification, Onthe, outbreak, outpatient, overallotment, passed, penny, pharmacy, pocket, prefunded, presidential, pro, proportionately, rata, refractory, Reg, regained, release, repay, residual, retroactive, ROU, soldpursuant, soliciting, SRC, Statute, sublicensee, substitution, syndrome, takeover, TCR, tech, tender, tisagenlecleucel, Treasurer, TRICARE, unclear, unconstitutional, unfolding, Vice, wecompleted, XBIOW, Yescarta, zone
Removed:
acting, Adult, affirmative, aforementioned, allocable, Altered, amend, American, amortization, anniversary, anthracycline, antineoplastic, April, assumption, assured, attempted, biomarker, breast, buyer, calculate, calling, carboplatin, catch, center, characterize, chemotherapeutic, cisplatin, cohort, collectability, compound, copy, cumulative, cytotoxic, Dana, depot, determinable, discharge, dispose, divided, dose, Downstream, doxorubicin, elucidate, Emergent, ER, estrogen, expiry, explanatory, exploratory, exposure, Farber, fifty, greatest, Harvard, Hematology, hemoglobin, ifosfamide, immunomodulatory, insensitive, judged, kinase, knowledge, leased, Ledgemont, Maguire, match, MD, Medicine, minimize, NE, negligible, organizational, pathway, percent, persuasive, PJSC, possession, presently, Professor, promissory, provisional, PulmoXen, ranking, receivable, reconciling, reorganization, restating, restructure, rh, Richard, Room, round, scheduled, School, Scott, Signaling, Simplifying, Society, staffing, standing, Stone, successor, suggest, surviving, Taxol, TEAE, TNBC, topotecan, travel, underwritten, unsolicited, Virexxa, Washington
Filing tables
Filing exhibits
- 10-K Annual report
- 4.1 Description of Registrants Securities Registered
- 10.50 Letter Agreement
- 10.51 Form of Letter Agreement
- 10.52 Stock Option Grant Notice
- 10.53 Stock Option Grant Notice
- 21.1 Subsidiaries of Registrant
- 23.1 Independent Registered Public Accounting Firm S Consent
- 31.1 Certification of Principal Executive Officer
- 31.2 Certification of Principal Financial Officer
- 32.1 Certification
- Download Excel data file
- View Excel data file
XBIO similar filings
Filing view
External links
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statement of Xenetic Biosciences, Inc. on Form S-8 (File Nos. 333-222272 and 333-218024), on Form S-3 (File Nos. 333-227572 and 333-233769) of our report dated March 26, 2020, with respect to our audits of the consolidated financial statements of Xenetic Biosciences, Inc. as of December 31, 2019 and 2018 and for each of the two years in the period ended December 31, 2019, which report is included in this Annual Report on Form 10-K of Xenetic Biosciences, Inc. for the year ended December 31, 2019.
/s/ Marcum LLP
Marcum LLP
Boston, Massachusetts
March 26, 2020